https://scholars.lib.ntu.edu.tw/handle/123456789/640201
標題: | Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study | 作者: | Kelly, William K Danila, Daniel C CHIA-CHI LIN Lee, Jae-Lyun Matsubara, Nobuaki Ward, Patrick J Armstrong, Andrew J Pook, David Kim, Miso Dorff, Tanya B Fischer, Stefanie Lin, Yung-Chang Horvath, Lisa G Sumey, Christopher Yang, Zhao Jurida, Gabor Smith, Kristen M Connarn, Jamie N Penny, Hweixian L Stieglmaier, Julia Appleman, Leonard J |
公開日期: | 12-一月-2024 | 卷: | 14 | 期: | 1 | 來源出版物: | Cancer discovery | 摘要: | Xaluritamig (AMG 509) is a six-transmembrane epithelial antigen of the prostate 1 (STEAP1)-targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such as those in advanced prostate cancer. This first-in-human study reports monotherapy dose exploration for patients with metastatic castration-resistant prostate cancer (mCRPC), primarily taxane pretreated. Ninety-seven patients received ≥1 intravenous dose ranging from 0.001 to 2.0 mg weekly or every 2 weeks. MTD was identified as 1.5 mg i.v. weekly via a 3-step dose. The most common treatment-related adverse events were cytokine release syndrome (CRS; 72%), fatigue (45%), and myalgia (34%). CRS occurred primarily during cycle 1 and improved with premedication and step dosing. Prostate-specific antigen (PSA) and RECIST responses across cohorts were encouraging [49% PSA50; 24% objective response rate (ORR)], with greater frequency at target doses ≥0.75 mg (59% PSA50; 41% ORR). Xaluritamig is a novel immunotherapy for prostate cancer that has shown encouraging results supporting further development. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/640201 | ISSN: | 21598274 | DOI: | 10.1158/2159-8290.CD-23-0964 |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。